VERNON W ANTHONY 4

What Happened
Vernon W. Anthony, a director of Nuvation Bio, was granted an award on May 21, 2026 covering 123,397 derivative shares (reported as acquisition code "A"). The filing shows an acquisition price of $0.00 for the award (total reported cash outlay $0). This is a compensation award/derivative grant rather than an open‑market purchase or sale.

Key Details

• Transaction date: May 21, 2026; Form 4 filed May 26, 2026 (appears filed after the typical 2-business-day Form 4 deadline).
• Instrument: derivative award/option (reported as "Grant, award or other acquisition (A)"); price reported $0.00.
• Shares involved: 123,397 derivative shares granted. Reported post-transaction ownership was not provided in the summary data.
• Footnote: 100% of the shares subject to the option vest on the earlier of (i) the one‑year anniversary of the grant date or (ii) the next shareholder annual meeting, subject to the reporting person’s continuous service through the applicable vesting date.
• No indication in the filing that shares were immediately sold or that the grant was part of a 10b5-1 plan or tax-withholding event.

Context
This was a compensation grant (derivative award) to a director, common for board or executive pay. Such awards are not purchases and do not directly signal buying or selling; their value depends on the company’s future stock price and vesting conditions. The later filing date may be a timeliness issue investors may note.